Across the most recent 4 stories covering Duane Boise — 25% negative, 75% neutral sentiment, averaging 6/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance
threshold before it is linked here — a story naming this entity only in passing, as
competitive context for an unrelated subject, does not qualify. That threshold exists
because earlier testing surfaced entity pages cluttered with tangential mentions: a story
about two unrelated companies merging could otherwise populate a third company's page
simply because it was named once for comparison, with no real event of its own. The
timeline below reflects genuine milestones and developments specific to this entity,
cross-referenced against the same source-verification standard applied to every story on
this site. Sentiment measures the directional read of each development for this entity
specifically, not the overall tone of the reporting, and impact weights how consequential
a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and
sentiment are derived.
Timeline
Rescheduling Hearing Testimony
Under subpoena, Dr. Akinfiresoye testifies in the marijuana rescheduling proceeding that marijuana fails the first three factors of the DEA's five-factor test, directly contradicting the HHS Schedule III recommendation.
ALJ Hearing on Marijuana Rescheduling
A seven-day administrative hearing is held in Arlington, Virginia, debating whether marijuana has a 'currently accepted medical use' without MMJ's testimony or evidence.
DEA Excludes MMJ from Rescheduling Hearing
The DEA denies MMJ International Holdings' request to participate in the upcoming administrative hearing, asserting that its evidence raises only questions of law.
Attorney General orders marijuana moved to Schedule III
The AG issues an order rescheduling state‑licensed medical marijuana and establishing a novel federal registration system for state marijuana businesses.
DEA Scientific Data Review Published
Dr. Luli Akinfiresoye authors the DEA's internal Scientific Data Review on marijuana, reportedly concluding that marijuana lacks sufficient, reproducible scientific evidence for accepted medical use.
MMJ files DEA bulk‑manufacturer application
MMJ International Holdings submits an application to manufacture active pharmaceutical ingredients for cannabinoid drugs, which remains pending nearly eight years later.
A D.C. Circuit review of the Attorney General’s April 2026 order moving medical marijuana to Schedule III puts administrative law front and center. MMJ International Holdings argues the AG skipped required rulemaking and evidentiary hearings, threatening the integrity of the Controlled Substances Act’s scheduling process.
DEA pharmacologist Dr. Luli Akinfiresoye testified that marijuana fails the agency's historical scientific standard for accepted medical use, directly contradicting the HHS recommendation to reschedule. This intra-agency conflict exposes the proposed Schedule III rule to a likely arbitrary-and-capricious challenge, redefining the evidentiary landscape for controlled substance rulemaking.
The MMJ International Holdings petition raises fundamental administrative law questions: can an agency issue a final rescheduling order before conducting the hearing required by the Controlled Substances Act? The D.C. Circuit’s answer will shape DEA’s authority over all future scheduling actions.
MMJ International Holdings alleges the DEA violated administrative law by excluding it from marijuana rescheduling hearings, despite spending $10 million on FDA-pathway development. The exclusion raises due process and APA concerns that could imperil the final rule.
This page surfaces every story mentioning Duane Boise across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent
relevance to the story, filtering out passing mentions. According to that methodology,
reviewed July 2026, this follows multi-source corroboration standards recommended by
journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
What you see
What it tells you
Story count
Number of distinct stories where Duane Boise was a primary or referenced actor.
Recency clustering
Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distribution
Aggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche links
When the same entity surfaces in our sibling networks, we link to those views to enrich context.